Formulation Development
WHITE PAPER - Nanoparticles in Drug Delivery & Photothermal Therapies
Download this white paper to learn more about the applications of silica and metal-based nanoparticles in drug delivery and photothermal therapy…..
FDA Approves Dermavant’s VTAMA (Tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the US in 25 Years
Dermavant Sciences recently announced the US FDA has approved VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes….
Lonza & Israel Biotech Fund Collaboration Framework Agreement to Support Biologics & Small Molecules Development & Manufacture for Portfolio Companies; IBF to Facilitate Access to Israeli Market
Israel Biotech Fund, a venture fund investing in Israeli and Israeli-related biotech companies, and Lonza, a global development and manufacturing partner to the pharma, biotech…
Clearmind Medicine & SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
Clearmind Medicine Inc. recently announced positive safety profile results from its joint preclinical trial with SciSparc Ltd. The trial evaluated the proprietary combination of Clearmind’s proprietary psychedelic molecule….
GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China
GeoVax Labs, Inc. recently announced the Chinese Patent Office has issued a Notice of Allowance for GeoVax’s patent application titled Compositions and Methods for Generating…
Synlogic Receives Positive Opinion on Orphan Designation From the EMA for SYNB1618 for the Treatment of Phenylketonuria
Synlogic, Inc. recently announced the European Medicines Agency (EMA) issued a positive opinion on the company’s application for orphan designation for SYNB1618 for the treatment…
Lonza Announces Expansion of Inhalation Capabilities at US Facility
Lonza, a global manufacturing partner to the pharma, biotech, and nutrition industries, recently announced it will invest in additional inhalation capabilities. The investment will fund…
COMPASS Pathways Presents Largest Ever Study of Psilocybin Therapy
COMPASS Pathways plc recently presented positive data from the largest randomized, controlled, double-blind study of psilocybin therapy ever completed, at the American Psychiatric Association annual…
Starton Therapeutics Announces Approval to Proceed With Final Dose Escalation in Phase 1 Clinical Study Evaluating STAR-LLD
Starton Therapeutics Inc. recently announced the Independent Data Monitoring Committee reviewed the totality of the safety data from the first two cohorts and recommended advancement…
Recce Pharmaceuticals Announces Positive Safety Data From Fifth Cohort of Phase 1 Clinical Trial
Recce Pharmaceuticals Ltd. recently announced that in cohort five of a Phase 1 clinical trial, R327 demonstrated a good safety and tolerability profile among 10…
Day One Announces First Patients Dosed in Phase 1b/2 Combination Study With Tovorafenib & Pimasertib in RAF-Altered Solid Tumors
Day One Biopharmaceuticals recently announced the first patients have been dosed in sub-study 2 of FIRELIGHT-1, a Phase 1b/2 clinical trial evaluating tovorafenib (DAY101) in…
Ajinomoto Licenses Genedata Bioprocess for Development of High-Performance Cell Culture Media
Genedata recently announced Ajinomoto has deployed Genedata Bioprocess to digitalize and automate their R&D and manufacturing operations in Japan and Korea…..
N4 Pharma Highlights Potential of Nuvec as Gene Therapy Delivery Platform
A recent preclinical in-vivo study found that Nuvec – N4 Pharma’s novel silica-based nanoparticle – formulated with TNF-α pDNA oncotherapy, suppressed tumor growth and improved survival of….
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients With p53-Mutated Neoadjuvant Breast Cancer
Aileron Therapeutics recently announced it has treated the first patients in its Phase 1b randomized, controlled clinical trial evaluating ALRN-6924 to protect against chemotherapy-induced neutropenia…
Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3
Biomea Fusion, Inc. recently announced the nomination of its second product candidate, BMF-500, a highly selective and potent covalent investigational third-generation….
Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease
Caladrius Biosciences, Inc. recently announced the Independent Data Monitoring Committee (IDMC) overseeing the Phase 1b, open-label, proof-of-concept study of CLBS201 for the treatment of diabetic kidney disease (DKD) has reviewed the initial safety….
Rafael Pharmaceuticals Announces Corporate Name Change to Cornerstone Pharmaceuticals
Rafael Pharmaceuticals, Inc. recently announced it is changing its name to Cornerstone Pharmaceuticals, Inc., its original company name. All company branding, including the website and…
Croda Announces the New Pharma Business
Croda recently announced that its Health Care division will now become Croda Pharma, bringing its core speciality excipient portfolio together with the recent acquisition, Avanti Polar Lipids and its….
Clarus Therapeutics Announces Issuance of Patent Covering JATENZO (Testosterone Undecanoate)
Clarus Therapeutics Holdings, Inc. recently announced that the United States Patent and Trademark Office (USPTO) has issued a new patent for claims that cover Clarus’ oral testosterone replacement product….
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma
Avalo Therapeutics, Inc. recently announced the first patient has been dosed in the company’s Phase 2 PEAK (A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group…
